As a consequence, FXR has been identified as an appealing target in the treatment of cholestasis disorders such as primary biliary cirrhosis (PBC) and liver steatosis9, 10, 11, two severe human conditions in which bile acids homeostasis is impaired. Here, NR1H4 is linked to primary biliary cholangitis.